Will New Joint Venture Lead to Faster West Nile Assay in Time for Season? | GenomeWeb

Spectral Diagnostics, a Canadian biotech shop, hopes to use approximately $8 million in cash and other investments to develop an in vitro diagnostic for West Nile virus that health-care workers can employ in the field, a company official told SNPtech Reporter.

While an immunoassay for the pathogen is currently approved for use in the United States, the test proposed by Spectral Diagnostics will require smaller blood samples, and may be able to provide results in minutes rather than hours or days.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.